Literature DB >> 15993591

SAR and biological evaluation of novel trans-3,4-dimethyl-4-arylpiperidine derivatives as opioid antagonists.

Nuria Díaz1, Mark Benvenga, Paul Emmerson, Ryan Favors, Michael Mangold, Jamie McKinzie, Nita Patel, Steven Peters, Steven Quimby, Harlan Shannon, Miles Siegel, Michael Statnick, Elizabeth Thomas, Joseph Woodland, Peggy Surface, Charles Mitch.   

Abstract

The phenolic hydroxy group of opiate-derived ligands is of known importance for biological activity. We have developed a SAR study around LY255582 by comparing the effect of the hydroxy group in the 2- and 4-position of the phenyl ring. Also, we have proved that the 3-position of the phenyl ring is optimal for opioid activity. Furthermore, we have successfully replaced the hydroxy group in LY255582 by carbamate and carboxamide groups. The new analogs have high affinity for the opioid receptors comparable to the corresponding phenol. Carboxamide analog 12 has an improved metabolism profile and proved to be efficacious in in vivo studies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15993591     DOI: 10.1016/j.bmcl.2005.05.123

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  2 in total

Review 1.  The discovery and development of the N-substituted trans-3,4-dimethyl-4-(3'-hydroxyphenyl)piperidine class of pure opioid receptor antagonists.

Authors:  F Ivy Carroll; Roland E Dolle
Journal:  ChemMedChem       Date:  2014-06-30       Impact factor: 3.466

2.  Design, synthesis, and biological evaluation of (3R)-1,2,3,4-tetrahydro-7-hydroxy-N-[(1S)-1-[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-3-isoquinolinecarboxamide (JDTic) analogues: in vitro pharmacology and ADME profile.

Authors:  Chad M Kormos; Moses G Gichinga; Rangan Maitra; Scott P Runyon; James B Thomas; Lawrence E Brieaddy; S Wayne Mascarella; Hernán A Navarro; F Ivy Carroll
Journal:  J Med Chem       Date:  2014-08-25       Impact factor: 7.446

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.